Clinical Trials

455 enrolled

Neoplasm Metastasis

NCT03498521 2025-11-19

CUPISCO

529 enrolled 16 charts

Phase 1/2 Active not recruiting

Neoplasms, Unknown Primary

NCT03202940 2025-09-25

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

16 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03596866 2025-09-12

ALTA-3

Phase 3 Completed

248 enrolled 20 charts

303 enrolled 31 charts 2 FDA

ALK+ Advanced NSCLC

NCT02075840 2025-07-25

ALEX

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT04341181 2025-07-25

ProTarget

300 enrolled

Phase 2 Active not recruiting

Neoplasms

NCT02314481 2025-05-23

DARWINII

50 enrolled

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Phase 1/2 Terminated

11 enrolled 21 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05525858 2025-04-27

KOSMOSII

Recruiting

1,000 enrolled

Neoplasm Metastasis

NCT03445000 2025-04-08

ALERT-lung

Phase 2 Terminated

14 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Active not recruiting

770 enrolled

Rare Tumor

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

72 enrolled

Neoplasm Metastasis

NCT04632992 2025-01-08

MyTACTIC

Phase NA Not yet recruiting

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT06709274 2024-11-29

MOTION-NSCLC

342 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04351334 2024-09-19

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

161 enrolled 19 charts

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05015010 2024-08-09

ALNEO

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

GastrointestinalGenitourinary

673 enrolled 22 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

111 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT05525338 2024-05-13

ADAPT ALEC

Phase 4 Recruiting

196 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06339554 2024-04-01

TOSS-ALK

98 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04817956 2024-02-29

IMPRESS-N

3,000 enrolled

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Phase EARLY_PHASE1 Withdrawn

Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05081674 2023-10-11

BLISS

154 enrolled